title: Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction.
abstract: The effect of acute myocardial infarction (AMI) on regional cardiac adrenergic function was studied in 27 patients mean +/- standard deviation 10 +/- 4 days after AMI. Regional adrenergic function was evaluated noninvasively with I-123 meta-iodobenzylguanidine (MIBG) using a dedicated 3-detector tomograph. Four hours after its administration, there was reduced MIBG uptake in the region of infarction, 0.38 +/- 0.31 counts/pixel/mCi x 103 compared with 0.60 +/- 0.30 counts/pixel/mCi x 103 and 0.92 +/- 0.35 counts/pixel/mCi x 103 in the zones bordering and distant from the infarct area, respectively, p less than 0.001. In all patients, the area of reduced MIBG uptake after 4 hours was more extensive that the associated thallium-201 perfusion defect with defect scores of 52 +/- 22 and 23 +/- 18%, respectively, p less than 0.001. After anterior wall AMI, the 4-hour MIBG defect score was 70 +/- 13% and the degree of mismatch between myocardial perfusion and MIBG uptake was 30 +/- 9% compared with 39 +/- 17 and 21 +/- 17% after inferior AMI, p less than 0.001 and p = 0.016, respectively. The 4-hour MIBG defect score correlated inversely with the predischarge left ventricular ejection fraction, r = -0.73, p less than 0.001. Patients with ventricular arrhythmia of greater than or equal to 1 ventricular premature complexes per hour, paired ventricular premature complexes or ventricular tachycardia detected during the late hospital phase had higher 4-hour MIBG defect scores, 62.5 +/- 15.0%, than patients with no detectable complex ventricular ectopic activity and a ventricular premature complex frequency of less than 1 per hour, 44.6 +/- 23.4%, p = 0.036.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
authors.forename: A I
authors.initials: AI
authors.lastname: McGhie
authors.forename: J R
authors.initials: JR
authors.lastname: Corbett
authors.forename: M S
authors.initials: MS
authors.lastname: Akers
authors.forename: P
authors.initials: P
authors.lastname: Kulkarni
authors.forename: M N
authors.initials: MN
authors.lastname: Sills
authors.forename: M
authors.initials: M
authors.lastname: Kremers
authors.forename: L M
authors.initials: LM
authors.lastname: Buja
authors.forename: M
authors.initials: M
authors.lastname: Durant-Reville
authors.forename: R W
authors.initials: RW
authors.lastname: Parkey
authors.forename: J T
authors.initials: JT
authors.lastname: Willerson
mesh_terms: D019797:3-Iodobenzylguanidine; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000150:complications; D002395:Catecholamines / Q000097:blood; D003287:Contrast Media; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013794:Thallium Radioisotopes; D014055:Tomography, Emission-Computed; D016277:Ventricular Function, Left
chemical_list: D002395:Catecholamines; D003287:Contrast Media; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013794:Thallium Radioisotopes; D019797:3-Iodobenzylguanidine